Aurora Cannabis (ACB)

Executive Summary

Aurora Cannabis (TSX/NASDAQ: ACB) is a Canadian licensed producer focused on medical and recreational cannabis. The company operates large-scale cultivation facilities and distributes products domestically and internationally. In recent quarters, Aurora has prioritized cost reduction and positive EBITDA, narrowing losses amid a challenging cannabis market. Its medical segment, with a portfolio of dried flower, oils, and edibles, continues to generate steady revenue. Meanwhile, recreational sales face pricing pressures and illicit competition. Aurora's international exposure, particularly in Germany and Australia, provides diversification as European markets expand. The company's research into cannabinoid therapies for chronic pain and anxiety positions it for potential medical adoption. However, regulatory uncertainty, especially around US federal legalization and Canadian excise taxes, limits near-term upside. Aurora's path to sustained profitability hinges on margin improvement and successful execution in high-growth international markets.

Upcoming Catalysts (preview)

• H2 2026US Federal Cannabis Rescheduling or SAFE Banking Passage35% success
• Q3 2026German Medical Market Expansion and EU-GMP Certification70% success
• Q4 2026Positive EBITDA and Path to Profitability in FY202655% success